HY01 by Heyu for sudden sensorineural hearing loss

ClinicalTrials.gov describes HY01 as a glucocorticoid drug administered by repeated intratympanic dosing for salvage treatment of sudden sensorineural hearing loss; the specific active corticosteroid was not publicly resolved in this pass.

Verified as a real Heyu-sponsored Phase 1 registry record for repeated intratympanic HY01 in sudden sensorineural hearing loss. The ClinicalTrials.gov record describes HY01 as a glucocorticoid drug and lists last-known status as recruiting, but the overall status is Unknown, the registry has not been updated since July 2021, and the estimated completion date has passed. No independent public company or publication corroboration was found in this pass, so HearScape should show this as a registry-verified, highly caveated candidate rather than a confirmed active program.